Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Delisting risk
confidence 95%
filed 2026-06-24
Item 8.01
The filing discloses that Femasys has regained compliance with Nasdaq Listing Rule 5550(a)(2) following a minimum bid price deficiency notice issued on July 16, 2025. While the company has now cured the deficiency through a 1-for-20 reverse stock split completed June 5, 2026, the core event is the resolution of a delisting risk that previously threatened the company's continued listing on Nasdaq. This is material to investors as it directly affects the company's ability to remain publicly traded.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-24
MIND CTI Ltd. received a Nasdaq letter on June 23, 2026 indicating non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)) requiring a minimum of $1 per share. The company has 180 calendar days until December 21, 2026 to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status and investor assessment.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-24
Item 3.01
Definitive Healthcare received written notice from Nasdaq on June 18, 2026, that it failed to meet the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). The company has 180 calendar days until December 15, 2026, to regain compliance, with the explicit warning that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-24
EX-99.1
The exhibit announces a 1-for-25 share consolidation explicitly undertaken to "regain compliance with Nasdaq Marketplace Rule 5550(a)(2) (minimum bid price of at least $1 per share) and maintain its listing on the Nasdaq Capital Market." This is a direct response to delisting risk triggered by failure to meet the minimum bid price rule, making it a material disclosure of action taken to avoid delisting.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-24
EX-99.1
Apollomics received a Nasdaq deficiency notice dated June 18, 2026, stating non-compliance with the minimum Market Value of Listed Securities (MVLS) requirement of $35 million under Nasdaq Listing Rule 5550(b)(2). The company has 180 calendar days (until December 15, 2026) to regain compliance or face delisting. This is a material disclosure of delisting risk under Item 3.01 equivalent for a foreign private issuer.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-24
The 6-K discloses that Kandal M Venture Limited received a Nasdaq deficiency letter on June 23, 2026, granting an additional 180-day compliance period (until December 21, 2026) to regain compliance with the minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2). The filing explicitly states that failure to comply by that date will result in written notification of delisting, with the company retaining appeal rights. This is a material delisting risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-24
Item 3.01
The filing discloses a final delisting determination by the Nasdaq Hearings Panel on June 23, 2026, with trading suspension effective June 25, 2026. The Company violated Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price) and 5550(b)(1) (minimum $2.5 million stockholders' equity), and the Panel denied the Company's request for continued listing despite a proposed SPAC merger and reverse stock split plan. This is a terminal delisting event, not merely a risk or notice of non-compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-24
Item 8.01
GD Culture Group received a Nasdaq notification on June 22, 2026, that its stock failed to maintain the minimum $1.00 bid price for 30 consecutive business days, triggering a compliance deficiency under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days until December 21, 2026, to regain compliance or face potential delisting.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-24
Item 3.01 discloses that on March 23, 2026, NYSE American notified the Company it was not in compliance with continued listing standards under Section 1003(f)(v) due to stock price falling below $0.10, and trading was halted. The Company is undertaking a 1-for-60 reverse split to regain compliance. This is a classic delisting-risk disclosure—the exchange has notified the registrant of non-compliance and the registrant is taking corrective action to avoid delisting.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-23
Item 3.01
DevvStream received a Nasdaq Hearings Panel determination to suspend its securities from Nasdaq effective June 24, 2026, due to noncompliance with the Minimum Bid Price Rule (Rule 5550(a)(2)) and failure to satisfy the Net Income Rule (Rule 5550(b)). The filing explicitly discloses the suspension decision and the Company's intent to appeal to the Listing Council, with shares expected to transfer to the Pink Limited Market and potentially OTCQB. This is a clear delisting risk event under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-23
EX-99.1
The exhibit announces a 30-for-1 reverse stock split effective June 23, 2026, explicitly stated as "primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining its Nasdaq listing." This disclosure directly addresses delisting risk and the company's remedial action to avoid loss of listing status, which is material to investors assessing the registrant's continued market access and trading liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-23
Item 8.01
SCWorx received a Nasdaq Hearings Panel decision on June 17, 2026 granting continued listing subject to strict compliance conditions: obtaining shareholder approval for a reverse stock split by July 22, 2026, effecting the split by August 3, 2026, and demonstrating a $1.00+ closing bid price for 20 consecutive trading days by August 28, 2026. Failure to meet these deadlines will result in delisting from Nasdaq. This is a material delisting-risk disclosure under Item 3.01 framework, as the company faces imminent delisting if conditions are not satisfied.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-23
EX-99.1
The exhibit is a press release announcing that Nasdaq has determined to delist Smart Digital Group Limited's securities pursuant to Nasdaq Listing Rule IM-5101-4, following an SEC trading suspension issued on September 29, 2025. The Company has until June 24, 2026 to appeal, and if no appeal is filed, trading will be suspended on June 26, 2026 and Nasdaq will file a Form 25-NSE to complete the delisting. This is a direct delisting determination notice, which is a material event affecting the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-23
Item 5.03
Smart Powerr Corp. effected a 1-for-10 reverse stock split on June 17, 2026, primarily to bring the company into compliance with Nasdaq Capital Market's minimum bid price requirement. The company acknowledged material uncertainty regarding its ability to timely regain or maintain compliance with continued listing standards.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-23
Item 8.01
The filing discloses that Smith Micro Software received a Nasdaq notice on June 23, 2025, regarding non-compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), was granted two successive 180-day cure periods, and ultimately regained compliance by June 22, 2026. This is a classic delisting-risk disclosure under Item 8.01 documenting the resolution of a continued listing deficiency. The event is material because it directly affects the registrant's ability to maintain its public listing.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-23
EX-99.1
The exhibit announces that TechCreate has filed an appeal to the NYSE American Listing Qualifications Panel in response to a Staff determination to commence delisting proceedings. The Company received notice on June 12, 2026 that NYSE American Staff determined to commence delisting proceedings based on an SEC trading suspension on February 2, 2026 related to alleged share manipulation. This is a direct disclosure of delisting risk and proceedings initiated by the exchange, which is material to investors' assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-23
The 6-K discloses a reverse stock split (1-for-2 consolidation) effective June 29, 2026, explicitly stated as undertaken "to regain compliance with Nasdaq Listing Rule 5550(a)(2)." This indicates the company had fallen below the minimum bid price requirement and faced delisting risk. The reverse split is a direct response to a continued listing rule violation, making this a delisting_risk disclosure.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-23
EX-99.1
QMMM received a Staff Delisting Determination from Nasdaq on June 17, 2026, notifying the Company that Nasdaq has determined to delist its securities pursuant to Listing Rule IM-5101-4, with an independent basis cited under Rule 5250(c)(1) for delay in filing Form 20-F. The Company intends to appeal and request a hearing before the Nasdaq Hearings Panel, but there is no assurance the Panel will approve the compliance plan. This is a direct delisting notice meeting the definition of delisting_risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-06-23
Item 8.01
ESS Tech received written notice from the NYSE indicating the Company did not satisfy the continued listing standard in Section 802.01C of the NYSE Listed Company Manual relating to the minimum share price requirement, as previously reported in a Form 8-K filed June 15, 2026.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-22
The filing discloses that TOP Financial Group has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)) after previously falling below the $1.00 per share threshold for 30 consecutive business days. While the company has now cured the deficiency, the disclosure of the prior non-compliance and the cure is a material delisting-risk event that would affect a reasonable investor's assessment of the company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-06-22
Item 3.03
Boxlight announced a 1-for-6 reverse stock split of Class A common stock, effective June 22, 2026, explicitly intended to increase the closing bid price above $1.00 per share to maintain compliance with Nasdaq Capital Market Listing Rule 5550(a)(2) (minimum bid price requirement). The reverse split was approved by the Board of Directors and represents a material governance action undertaken to mitigate delisting risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-22
Item 8.01
Hydrofarm received a Nasdaq extension letter on June 16, 2026, indicating the company failed to maintain minimum stockholders' equity of $2,500,000 under Nasdaq Listing Rule 5550(b). The filing explicitly states that if the company fails to evidence compliance by its Q3 2026 periodic report filing, "the Company may be subject to delisting." This is a direct notice of delisting risk and failure to satisfy continued listing requirements, the hallmark of the delisting_risk event type.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-22
Item 8.01
The filing discloses two material listing compliance failures: (1) stockholders' equity of $9.0 million fell below the $10 million Nasdaq Global Market minimum, triggering a transfer to Nasdaq Capital Market effective June 23, 2026; and (2) the stock price has closed below the $1.00 minimum bid price requirement for 30 consecutive business days, with an initial 180-day cure period ending September 14, 2026. The company explicitly acknowledges "there can be no assurance that the Company will be able to regain compliance," creating a material delisting risk that would substantially affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-18
EX-99.1
Akanda received a Nasdaq notice on June 16, 2026 indicating non-compliance with Listing Rule 5550(b)(1) due to stockholders' equity of negative $11.99 million, falling below the required $2.5 million minimum. The company has 45 days to submit a compliance plan or face delisting. This is a direct notice of failure to satisfy a continued listing rule, the defining characteristic of delisting_risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-18
Item 8.01
The Company received a notice from NYSE American on May 27, 2026, indicating non-compliance with continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide due to insufficient stockholders' equity ($4.0 million minimum required) combined with losses in three of four recent fiscal years. The June 18, 2026 submission of a compliance plan is a direct response to delisting risk and represents a material disclosure of failure to satisfy a continued listing rule.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-18
Item 8.01
The filing discloses that Silo Pharma has regained compliance with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement after previously falling out of compliance in June 2025. While the current disclosure is positive (compliance restored), the underlying event—a delisting risk triggered by failure to maintain the $1.00 minimum bid price—is material to investors' assessment of the company's listing status and market viability. The company explicitly references the prior non-compliance letter and confirms that Nasdaq "considers this matter closed," indicating resolution of a previously disclosed delisting threat.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-18
Dyadic received a notification from Nasdaq on June 18, 2026 initiating delisting proceedings due to failure to maintain the minimum $1.00 bid price (Nasdaq Listing Rule 5450(a)(1)) and failure to meet continued listing standards under Rule 5550(b). The company has neither regained compliance nor met conditions for extension as of the filing date, and faces potential delisting despite plans to request a hearing before a Nasdaq panel.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-18
The filing discloses a Nasdaq notification letter (Item 3.01) stating that Algorhythm Holdings' common stock has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has been granted a 180-calendar-day compliance period (until December 14, 2026) to regain compliance, with potential delisting if it fails to do so. This is a clear delisting risk disclosure that would materially affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-18
The 6-K discloses that ZOOZ Strategy Ltd. received a Nasdaq notice on December 16, 2025, for non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) due to closing bid prices below $1.00 for 30 consecutive business days. The company was given 180 days to regain compliance by June 15, 2026. The filing now reports that the company has regained compliance as of June 12, 2026, and Nasdaq has formally closed the deficiency matter. This is a material delisting-risk disclosure because it directly addresses a continued listing rule violation and the company's status in regaining compliance.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-18
EX-99.1
K Wave Media received a written notification from Nasdaq dated June 16, 2026, stating the Company is not in compliance with the minimum $15,000,000 Market Value of Publicly Held Shares (MVPHS) requirement for continued listing on The Nasdaq Global Market. The Company has a 180-calendar-day compliance period to restore compliance, or face delisting. This is a clear notice of failure to satisfy a continued listing rule under Item 3.01 of the 8-K taxonomy.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-17
Item 3.01
Sleep Number received written notice from Nasdaq on June 16, 2026, that its common stock will be delisted from Nasdaq effective June 23, 2026, pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1. The delisting was triggered by the Company's Chapter 11 bankruptcy filing on June 12, 2026, and associated concerns about residual equity interest and ability to sustain listing compliance. This is a definitive delisting notice, not merely a risk or warning, making it a material event that fundamentally affects the trading and liquidity of the Company's securities.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-17
Item 3.01
The filing discloses a notice of delinquency from NYSE Regulation on May 19, 2026, for failure to timely file the Form 10-Q, triggering Section 1007 procedures and subjecting the Company to potential suspension and delisting. Although the Company subsequently filed the Form 10-Q on June 12, 2026, and regained compliance by June 15, 2026, the core event disclosed under Item 3.01 is the delisting risk and the Company's path through the compliance remediation process. This is material to investors as it reflects a serious breach of listing standards and the threat of delisting, even though the immediate risk was cured before the 8-K filing date.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-17
EX-99.1
The press release announces that Wing Yip Food Holdings has regained compliance with Nasdaq Listing Rule 5550(a)(2) after previously falling below the US$1.00 minimum bid price requirement on December 22, 2025. This disclosure directly addresses a delisting risk — the company was non-compliant with a continued listing standard and faced potential delisting, but has now cured the deficiency. The resolution of a delisting-risk event is material to investors assessing the registrant's continued exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-17
Item 7.01
The disclosure centers on the Company's regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule") after having been in violation as of December 19, 2025. While the news is positive (compliance restored), the core material event is the resolution of a delisting risk — the Company was previously at risk of delisting due to insufficient stockholders' equity and has now satisfied Nasdaq's requirements, subject to maintaining $5 million in equity for twelve months. This directly addresses a continued listing qualification matter under Item 3.01 principles, making it a delisting_risk classification.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-17
EX-99.1
The press release announces a 1-for-3 reverse stock split explicitly undertaken to "regain compliance with Nasdaq's Minimum Bid Price Requirement and Protecting Continued Listing Status." The company states it fell below the $1.00 minimum bid price threshold and faces potential delisting under Nasdaq Listing Rule 5810(c)(3)(A) if it does not comply. This is a material disclosure of delisting risk and the remedial action taken to address it.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-17
The 6-K discloses a Nasdaq deficiency notice dated June 11, 2026, informing Scage Future that its ADSs failed to maintain the minimum $1.00 bid price required by Nasdaq Listing Rule 5550(a)(2). The Company has until December 8, 2026 to regain compliance or faces potential delisting. This is a material delisting risk disclosure that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-17
EX-99.1
J-Star received a Staff Delisting Determination Letter from Nasdaq on June 12, 2026, for failure to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company is requesting a hearing before the Nasdaq Hearings Panel to appeal the determination and request additional time to regain compliance. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-17
The filing discloses Item 3.01 notification from Nasdaq that Vestand Inc. failed to regain compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) during its 180-calendar-day compliance period ending June 10, 2026, and is ineligible for an additional compliance period. The company faces a Nasdaq Hearings Panel determination on continued listing, with suspension and delisting risk pending the outcome of its appeal. This is a material delisting risk event.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-16
EX-99.1
Biophytis announces temporary suspension of trading of its shares on Euronext Growth Paris effective June 15, 2026, due to non-publication of the annual financial report for fiscal year 2025. The suspension results from an "operational delay in the preparation of financial statements" and trading is expected to resume only after publication of the audited annual report (expected no later than end of July 2026). This is a material delisting risk event — a failure to satisfy continued listing requirements (timely filing of annual financial statements) that has triggered an exchange-imposed trading suspension, directly threatening the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-16
Item 3.01
The filing discloses a delisting notice from Nasdaq under Item 3.01, specifically that MaxCyte's stock fell below the $1.00 minimum bid price requirement for 30 consecutive trading days, triggering non-compliance with Nasdaq Listing Rule 5450(a)(1). Although the company subsequently regained compliance by June 9, 2026, the initial delisting risk and the regulatory process itself are material events that would affect investor assessment of the company's listing status and market viability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-16
Item 3.01
Assertio Holdings notified Nasdaq to halt trading and delist its shares effective June 16, 2026, in connection with the merger closing. The company intends to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-16
Item 3.01
Following completion of the merger, Kennedy-Wilson requested and obtained suspension of trading of its common stock on the NYSE, and initiated delisting from the NYSE and deregistration under Section 12(b) of the Exchange Act via Form 25, with intent to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-16
EX-99.1
The press release announces that NYSE American has commenced delisting proceedings against JM Group Limited, determining that the Company's ordinary shares are unsuitable for continued listing pursuant to NYSE American Company Guide Sections 1001, 1002(e), and 1003. The Company has until June 19, 2026 to request a review. This is a direct delisting notice that materially threatens the Company's continued listing status and would significantly affect investor assessment.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-16
The SEC issued a trading suspension order on June 11, 2026, effective June 12–26, 2026, citing potential market manipulation via social media recommendations. The Company also received an information request from Nasdaq. While the suspension is temporary (15 days), trading suspensions are a direct precursor to delisting and represent a material threat to continued listing eligibility. The disclosure of SEC enforcement action and regulatory scrutiny satisfies the materiality threshold for a reasonable investor.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-16
Item 8.01
The filing discloses that Bridgeline Digital initially failed to maintain the Nasdaq minimum bid price requirement of $1.00 per share (notified January 29, 2026), triggering delisting risk under Nasdaq Listing Rule 5550(a)(2). Although the company subsequently regained compliance by June 10, 2026, the disclosure of the initial non-compliance and the cure period is a material event that would affect investor assessment of listing status and regulatory standing.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-16
The 6-K discloses that Genenta has regained compliance with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement ($1.00 per share) after previously falling out of compliance on April 10, 2026. While the current disclosure is positive (regaining compliance), it directly addresses a delisting risk that was material to investors. The resolution of a previously disclosed delisting threat is itself material and falls within the delisting_risk category as it concerns continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-16
Item 8.01
The disclosure centers on Lunai's regained compliance with Nasdaq's minimum bid price rule but explicitly details heightened delisting risk going forward. The company is now subject to a mandatory one-year Panel monitor with no cure period if it falls out of compliance again—a material change in listing status that would directly affect investor assessment. The language regarding automatic delist determination and loss of compliance flexibility signals elevated delisting risk despite the current compliance status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-15
EX-99.1
The press release announces that Sinovac "regained compliance with Nasdaq Global Market's listing requirements" after receiving a notification letter dated June 10, 2026, from the Nasdaq Hearing Advisor. This disclosure directly addresses a prior delisting risk or non-compliance status. The company remains under "Mandatory Panel Monitor" until May 20, 2027, indicating it was previously out of compliance with Listing Rule 5250(c)(1). This is a material event affecting the registrant's continued listing status on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-06-15
Item 3.01
Functional Brands Inc. received a written Staff Delisting Determination from Nasdaq on June 9, 2026, pursuant to the Low Priced Stocks Rule, triggered by the Company's closing bid price of $0.10 or less for ten consecutive trading days. Trading suspension is scheduled for June 16, 2026, with a Form 25-NSE to be filed to remove the Company's securities from listing, though the Company intends to appeal before a Panel and demonstrate a plan to regain compliance.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-15
EX-99.1
NYSE American announced on June 11, 2026, its intention to commence delisting proceedings against TechCreate Group Ltd. and has suspended trading of the Company's Class A ordinary shares. The statement explicitly references NYSE American's citation of Section 1002(e) and Sections 1001 and 1003 of the NYSE American Company Guide as the basis for the delisting decision. This is a clear notice of delisting risk and transfer of listing status, which materially affects investor assessment of the registrant's continued public trading eligibility.
View raw filing on EDGAR →